Deep Data Dive: Highlights From ASCO 2024 on the Treatment of High-Risk BCG-Unresponsive NMIBC : Episode 10
Opinion
Video
Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management
Panelists discuss how the combination therapy of cretostimogene plus pembrolizumab offers a promising new approach for managing BCG-unresponsive non-muscle-invasive bladder cancer, highlighting its potential benefits and the implications of its FDA Breakthrough Therapy Designation for clinical practice.
Video content above is prompted by the following questions:
- In your opinion, what does cretostimogene plus pembrolizumab combination therapy offer to the management of BCG-unresponsive NMIBC?
- Cretostimogene plus pembrolizumab received an FDA Breakthrough Therapy Designation in May 2023. What is important for physicians to know or understand about this designation?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Vignesh Packiam, MD, on choosing between options in NMIBC
Strategies to bridge gender disparities in AAS and citations in the oncology literature
Case 3: A 49-Year-Old Man With Recurrent Non–Muscle-Invasive Bladder Cancer
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
Study findings highlight gender gaps in oncology authorship and citation
Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Related Content
